GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Omadacycline (Nuzyra)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Nuzyra

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

NUZYRA - adult indication-specific loading and renal guidance

Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure
No renal-function dose bands specified for this summary.

Dosing / renal protocol and limits

Adults: IV loading for CABP or ABSSSI is 200 mg over 60 minutes on day 1, or 100 mg over 30 minutes twice on day 1. Maintenance is 100 mg IV over 30 minutes daily or 300 mg orally daily, for 7-14 days.

Oral-only loading differs: CABP uses 300 mg twice on day 1; ABSSSI uses 450 mg daily on days 1 and 2. Do not exchange these loading schedules.

No adjustment is required for renal impairment, including hemodialysis, or hepatic impairment.

For oral doses, fast at least 4 hours beforehand; afterward avoid food/drinks except water for 2 hours, and dairy, antacids and multivitamins for 4 hours.

Source revision: DailyMed updated 2026-05-27; prescribing information revised 2026-05 | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

NUZYRA - adult indication-specific loading and renal guidance

Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - omadacycline

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeNUZYRA - adult indication-specific loading and renal guidanceUCSF - omadacycline
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1

Product and population scope

Adult Omadacycline (Nuzyra). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-omadacycline · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

NUZYRA - adult indication-specific loading and renal guidance

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2026-05-27; prescribing information revised 2026-05
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adults: IV loading for CABP or ABSSSI is 200 mg over 60 minutes on day 1, or 100 mg over 30 minutes twice on day 1. Maintenance is 100 mg IV over 30 minutes daily or 300 mg orally daily, for 7-14 days.

Oral-only loading differs: CABP uses 300 mg twice on day 1; ABSSSI uses 450 mg daily on days 1 and 2. Do not exchange these loading schedules.

No adjustment is required for renal impairment, including hemodialysis, or hepatic impairment.

For oral doses, fast at least 4 hours beforehand; afterward avoid food/drinks except water for 2 hours, and dairy, antacids and multivitamins for 4 hours.

RDM30-092-omadacycline-1 · Source locator: NUZYRA - adult indication-specific loading and renal guidance; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1
Retrieved
2026-09-05
DailyMed Set ID
51591524-4703-44c6-8bde-dce3e6a463d1
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2026-05-27; prescribing information revised 2026-05
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
589cf7e806f56d8adb8da22bdef6d5919533f65246f12f9b66674d13e895a204
Separate professional-source layer

University and professional protocols

Professional

UCSF - omadacycline

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

The institutional IV schedule is 200 mg once followed by 100 mg daily. The listed oral schedule is 450 mg daily for two doses followed by 300 mg daily. The source does not reduce these regimens for renal dysfunction or HD.

Oral administration requires at least 4 hours fasting before and 2 hours after a dose. Loading may be omitted for selected NTM regimens under specialist care. Indication-specific product labeling must be checked separately; the displayed oral loading schedule is not automatically appropriate to every labeled infection.

RDM30-051-omadacycline-1 · Source locator: UCSF - omadacycline; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/omadacycline
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
fe33210c3e984ab366036fcb848c1298b62d129677442df58610511d4099988e

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51591524-4703-44c6-8bde-dce3e6a463d1
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
dad2926125d43513529be355404e6b95e892dca09a28dcc63157b12f6e3541fe
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report